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provided it is propeObjectives: To examine the impact of serum-derived bovine immunoglobulin, an oral
medical food known to neutralize bacterial antigen and reduce intestinal inflammation,
on restoration of mucosal immunity and gastrointestinal function in individuals with
HIV enteropathy.
Design: Open-label trial with intensive 8-week phase of bovine serum immuno-
globulin (SBI) 2.5 g twice daily with a 4-week washout period and an optional 9-month
extension study.
Methods: HIV enteropathy was defined as chronic gastrointestinal symptoms
including frequent loose or watery stools despite no identifiable, reversible cause.
Upper endoscopy for tissue immunofluorescent antibody assay and disaccharide gut
permeability/absorption studies were performed before and after 8 weeks of SBI to test
mucosal immunity and gastrointestinal function. Blood was collected for markers
of microbial translocation, inflammation, and collagen kinetics. A validated gastro-
intestinal questionnaire assessed changes in symptoms.
Results: All eight participants experienced profound improvement in symptoms with
reduced bowel movements/day (P¼0.008) and improvements in stool consistency
(P¼0.008). Gut permeability was normal before and after the intervention, but D-xylose
absorption increased in seven of eight participants. Mucosal CD4þ lymphocyte
densities increased by a median of 139.5 cells/mm2 from 213 to 322 cells/mm2
(P¼0.016). Intestinal-fatty acid binding protein (I-FABP), a marker of enterocyte
damage, initially rose in seven of eight participants after 8 weeks (P¼0.039), and
then fell below baseline in four of five who continued receiving SBI (P¼0.12). Baseline
serum I-FABP levels were negatively correlated with subsequent rise in mucosal CD4þ
lymphocyte densities (r¼0.74, P¼0.046).
Conclusion: SBI significantly increases intestinal mucosal CD4þ lymphocyte counts,
improves duodenal function, and showed evidence of promoting intestinal repair in the
setting of HIV enteropathy.  2013 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2013, 27:2207–2217ippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Early in the HIVepidemic, gastrointestinal-related disease
was a dominant presenting symptom complex. Jarry et al.
[1] utilized histopathologic evaluations of the gut
to demonstrate the profound immune depletion in
gastrointestinal-associated lymphoid tissue (GALT)
caused by HIV infection. HIV enteropathy became
known as the syndrome of gastrointestinal complaints that
persisted despite completion of appropriate therapy for
any identified abnormalities [2,3]. It was believed to be
due to HIV infection within the gastrointestinal mucosa,
if not the enterocytes themselves, resulting in defects of
mucosal function [4,5]. Despite the improvements in
morbidity and mortality related to HIV infection [6],
diarrhea and related gastrointestinal complaints remain in
nearly 30% of patients on antiretroviral therapy (ART)
[7,8].
GALT is recognized as a primaryHIV target, irrespective of
the mode of transmission, likely due to its constitutively
high level of activation [9,10]. Within weeks of infection,
human and nonhuman primate studies demonstrate
infection of virtually all susceptible CD4þ T lymphocytes
with HIV [11–13]. Despite effective ART, lymphocyte
recovery in duodenal lamina propria lags far behind
immune reconstitution in the peripheral blood compart-
ment [14–16].
Depletion of lymphocytes in GALT leads to bacterial
translocation, irrespective of the mechanism for cell loss
[17,18]. Consequences of HIV-induced CD4þ T-cell
depletion from GALT and microbial translocation as
measured by plasma concentrations of lipopolysaccharide
(LPS) and bacterial 16S ribosomal-RNA gene sequences
(rDNA) include increased levels of proinflammatory
cytokines and peripheral blood CD8þ T-cell subsets with
an activated phenotype [19,20]. We have performed
preliminary studies showing that the composition of
the gut microbiota is correlated with both duodenal
mucosal T-cell distribution and activation, as well as
systemic immune activation in HIV patients both naı¨ve or
receiving ART [21].Bovine serum immunoglobulin (SBI) is a specially
formulated medical food that provides distinct nutritional
support for the clinical dietary management of
enteropathy under medical supervision. It is widely used
in animal husbandry to reduce severe gastrointestinal
manifestations of inflammation in young animals [22,23].
Animal model experiments of intestinal inflammationpincott Williams & Wilkins. Unauthodemonstrate that the immunoglobulins present in SBI
neutralize LPS and other bacterial antigens and improve
intestinal barrier function damaged by bacterial toxins
[24–27]. This oral immunoglobulin undergoes reversible
conformational changes under gastric pH and other-
wise passes through the intestines unabsorbed. Available
commercially, it has a long history of safety, including in
children [28]. The hypothesis pursued in this clinical trial
was that neutralization of proinflammatory bacterial
antigen in the gut by SBI would lead to restoration
of mucosal immunity and gastrointestinal function.
We targeted study participants with a diagnosis of
HIV enteropathy for this clinical trial as this population
likely has an underlying disturbance in gut microbiota
composition and altered gastrointestinal function as a
feature of their immunopathology.Methods
Study design
This open-label pilot study enrolled participants with
the diagnosis of HIV enteropathy to receive 2.5 g of
SBI (EnteraHealth, Akeny, Iowa, USA) twice daily for
8 weeks followed by a 4-week washout phase. HIV
enteropathy was defined as chronic gastrointestinal
symptoms including loose or watery stools and increased
stool frequency (>3/day) despite no identifiable,
reversible cause. Participants with gastrointestinal symp-
toms after the washout phase were invited to enter into an
extension period for an additional 9 months. Screening
studies included stool samples for Clostridium difficile
toxin, enteric pathogens, antigen testing for giardia,
cryptosporidium, Entamoeba histolytica, Helicobacter pylori,
and stains for ova and parasites, acid-fast bacilli,
microsporidia, and isospora. Screening tests performed
for food intolerance included endomysial antibodies to
exclude gluten allergy and a period of lactose-free diet if
indicated. ART-associated gastrointestinal intolerance
was assessed either by a history of symptoms predating
treatment initiation or persistence of symptoms despite a
change in regimen. Continuation of stable, chronic
antimotility agents was permitted with the provision that
increases in doses were avoided. Study entry was delayed
at least 4 weeks following antibiotic administration
except for chronic Pneumocystis pneumonia prophylaxis.
Participants underwent phlebotomy and stool submission
at preentry and entry visits, at weeks 7 and 8 while
receiving SBI, at week 12 after a 4-week washout, and
then again at the end of 48 weeks for those participantsrized reproduction of this article is prohibited.
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available from a cohort of controls for comparison (n¼ 8).
Analysis performed on the last sample available for a
participant (end of treatment – EOT) was week 8 or
week 48. All participants signed an informed consent
form approved by the UC Davis Institutional Review
Board [Clinical Trial Registry (Clinicaltrials.gov):
NCT01313910].
Gastrointestinal questionnaire and food diary
A licensed dietician met with participants to assess food
intolerance prior to enrollment and throughout the first
12 weeks to review a food diary. A steady diet was
maintained in order to not confound observed clinical
results. A validated gastrointestinal questionnaire, com-
pleted at each study visit, recorded daily stool frequency,
stool consistency relying on a pictorial scale from
1 (normal, formed) to 6 (water, puddle-like), and
gastrointestinal symptoms over the previous week [7].
The questions assessed symptoms including cramping,
urgency, incontinence, and nocturnal bowel movements
(possible score from 0 to 39 with normal <4).
Gastrointestinal function assays: rhamnose/
lactulose gut permeability and D-xylose
absorption study
The disaccharide gut permeability and D-xylose
absorption study were performed in the week preceding
study entry and after 7 weeks of SBI treatment.
Participants consumed a syrup consisting of lactulose
(5 g), L-rhamnose (1 g), and D-xylose (500mg; BCM
Specials Products, London, UK) on an empty stomach
and collected all urine over the subsequent 4 h [29]. Urine
disaccharide levels were measured in the laboratory of
Dr Roy Sherwood [30]. Results are reported as the
ratio of lactulose/L-rhamnose (normal <0.05). Duodenal
absorption function is reported as the amount of D-xylose
collected in the urine over 4 h.
Upper endoscopy and tissue processing
Distal duodenum biopsies were obtained before and
8 weeks after initiating SBI. Tissue was either paraffin-
embedded for routine histology and immunofluorescent
antibody assay (IFA) or underwent digestion to single-
cell suspension for polychromatic flow cytometry as
previously described [31]. Peripheral blood mononuclear
cells (PBMCs) were separated by Ficol-Hypaque and
processed with the duodenal cells in identical fashion.
Fluorescence-activated cell analysis was performed
on a custom Becton-Dickinson LSRII cytometer and
analyzed with FlowJo (TreeStar, Ashland, Oregon, USA).
For IFA analysis, the primary antibodies were polyclonal
anti-CD3 rabbit serum (Dako Inc., Carpinteria,
California, USA) and monoclonal anti-CD4 or CD8
mouse serum (Leica Microsystems, Buffalo Grove,
Illinois, USA). Binding of CD3þ and CD4þ or CD8þ
receptors was detected simultaneously using AlexafluorCopyright © Lippincott Williams & Wilkins. Unaut488-labeled polyclonal goat antirabbit IgG and Alexafluor
568-labeled polyclonal goat antimouse IgG (both
Molecular Probes, Eugene, Oregon, USA). Positive
cells were counted by a single observer (Z.-M.M.) and
presented as cells/mm2 of lamina propria or intraepithe-
lial regions of duodenal mucosa [16,32,33] (Fig. 1).
Measurement of markers of microbial
translocation, inflammatory cytokines, and
fibrosis/collagen kinetics
LPS was performed on serum obtained using pyrogen-
free vacutainers as well as the standard serum separator and
EDTA tubes for plasma with the Lonza LAL QCL-1000
kit (Lonza, Walkersville, Maryland, USA) according
to the manufacturer’s protocol in duplicate. Plasma
LPS-binding protein (LBP) and bactericidal/permeability
increasing protein (BPI; Uscn Life Science Inc., Missouri
City, Texas, USA) were quantified by ELISA according to
the manufacturer’s protocol. Intestinal fatty acid binding
protein (I-FABP; R&D Systems, Minneapolis, Minne-
sota, USA) was measured on serum diluted to 10% in
sCD14 dilution buffer. Levels of proinflammatory
(interleukin-1b [IL-1b], IL-6, tumor necrosis factor-a
[TNF-a]), Th1 (interferon-g [IFN-g] and IL-12p70),
Th2 (IL-4 and IL-10), and regulatory (IL-10) cytokines,
chemokines (IL-8, and monocyte chemoattractant
protein-1 [MCP-1], and biomarkers of collagen regula-
tion (hyaluronic acid, transforming growth factor-b
(TGF-b), matrix metalloproteinases-1 [MMP-1], MMP-
9, tissue inhibitor of metalloproteinases-1 [TIMP-1],
and TIMP-2) were all measured with multiplex enzyme-
linked immunosorbent assay (ELISA)-based assays
(MesoScale Discovery) except for hyaluronic acid
(Corgenix, Broomfield, Colorado, USA).
Statistical approaches
Nonparametric statistical methods were used throughout.
Wilcoxon matched-pairs signed rank test was used for
assessing changes between baseline and postintervention
results and Mann–Whitney test was used to compare
participants with normal control samples. The Spearman
rank correlation coefficient was used to study correlations
between parameters. All values are represented as
the median (interquartile ranges) unless otherwise stated.
As a pilot project designed to explore hypotheses
for a larger placebo-controlled trial, no adjustments for
multiple comparisons were included [34]. Analyses
were performed with GraphPad Prism Software V5.0
(GraphPad Software, Inc., La Jolla, California, USA).Results
Participant demographics and clinical results
All eight participants were men (five white, three
African–American) with a median age of 44.5 years
(38.8–47.8) and a peripheral blood CD4þT-cell count ofhorized reproduction of this article is prohibited.
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Fig. 1. Immunofluorescent antibody assay for T-lymphocyte populations in duodenal tissue. Representative examples from
CD3þ/CD4þ and CD3þ/CD8þ staining before and after 8 weeks of bovine serum immunoglobulin (SBI) are shown. The dotted
lines demark the intestinal lumen from the epithelial layer and the dashed lines demark the basement membrane of the epithelial
layer from the lamina propria. Nuclei stained blue with 4’,6-diamidino-2-phenylindole (DAPI); background tissue pale green.
Double-positive cells fluoresce a pale red-orange and are recorded as the number of positive cells per mm2 of lamina propria or
epithelial zone. Slides were visualized with epifluorescent illumination using a Zeiss Axioplan 2 microscope (Carl Zeiss Inc.,
Thornwood, New York, USA) with a x40/0.75 plain neofluar objective (Carl Zeiss Inc.) and appropriate filters (Omega Optical,
Brattleboro, Vermont, USA) at room temperature. Digital images were captured by using a QImaging Micropublisher 5.0 RTV
camera (QImaging, Surrey, Canada) and Openlab software (Inprovision, Waltham, Massachusetts, USA). Five fields per section
were randomly chosen. Color images were captured by only adjusting the exposure time without other modification.
IFA, immunofluorescent antibody assay.372 cells/ml (193–459). All had been on ART for more
than 1 year, including four on protease inhibitor-based,
three on nonnucleoside reverse transcriptase inhibitor-
based, and one on integrase inhibitor-based regimens
with consistently undetectable viral loads. Two partici-
pants had CD4þ T-cell counts below 200 cells/ml and
were on chronic trimethoprim-sulfamethoxazole pro-
phylaxis therapy. The specimens from controls were
used from a study with similar procedures including
duodenal biopsies and stool and blood collection reported
previously [16].
All tolerated SBI well with excellent compliance initially,
as determined by pill counts, which declined during the
extension period. Ironically, the only ‘adverse event’
reported by participants was perceived constipation
when stool frequency fell to once a day in two of the
participants. Three were either lost to follow-up or did
not have a rebound of symptoms after the washout period
and five completed the 48 weeks of observation on SBI.
Thus, EOTanalysis is at week 48 for five participants and
week 8 for three participants. All participants experiencedpyright © Lippincott Williams & Wilkins. Unauthoa consistent improvement in symptoms after 2–3 weeks,
and all five participants on chronic antimotility agents
at baseline only used them sporadically at the most.
Bowel movements/day decreased from 5.8 (5.0–8.4) to
2 (2–3.8; P¼ 0.008), stool consistency [1-formed to
6-watery] decreased from 5.3 (5–6) to 3 (2.2–3.8;
P¼ 0.008), and the gastrointestinal questionnaire score
decreased from 17 (15.6–21.8) to 8.0 (3.5–11.9;
P¼ 0.008) at week 8 compared to baseline (Fig. 2).
Participants who were experiencing urgency with
episodes of soiling or night-time bowel movements
reported complete resolution of such episodes. For those
five who continued SBI to week 48, durable bowel
movements/day, stool consistency, and questionnaire
responses were reported at 2.0 (2.0–3.0), 2.5 (1.0–3.8),
and 6.0 (2.0–12.8), respectively (all P¼ 0.062 compared
to baseline).
Intestinal permeability and absorptive function
Interestingly, as measured by the gold standard disacchar-
ide absorption test, increased intestinal permeability
was not observed in this cohort of participants. This isrized reproduction of this article is prohibited.
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Fig. 2. Gastrointestinal questionnaire. Participants responded to a validated questionnaire using a 1-week recall to record number
of bowel movements/day (a), the typical – ‘most of the time’ – consistency of the stool using a pictorial scoring scale for solid [1] to
watery [6] (b), and series of questions eliciting symptoms covering abdominal pain, urgency, incontinence, and nighttime bowel
movements with a scoring scale that has a maximum of 39 points (c).consistent with previous reports in HIV individuals
without intestinal pathogens [30,35,36]. Gut perme-
ability was normal before [0.024% (0.0–0.048)] and
after [0.032% (0.0–0.047)] intervention (Fig. 3a).
However, D-xylose urinary excretion, reflecting distal
duodenal absorption function, increased in seven of eight
participants with an overall increase from a median of
33.8mg (28.7–38.2) at baseline to 40.9mg (19.8–44.4)
at week 7 (P¼ 0.19; Fig. 3b) [5].
Histopathology and immunologic responses
Hematoxylin and eosin stain demonstrated mild reduc-
tion of the villus to crypt ratio of 2.1 (normal 3.0)
overall. Focal tip apoptosis and nonspecific chronic
inflammation were noted in four of eight without a trend
related to SBI administration. Peripheral CD4þ T-cell
counts were unchanged at 339 cells/ml (210–468) after
8 weeks and 348 cells/ml (225–397) after 48 weeks.Copyright © Lippincott Williams & Wilkins. Unaut
Ba
se
line
we
ek
 7 
0.00
0.05
0.10
0.15
0.20
Pe
rm
ia
bi
lity
 ra
tio
 
(a) (b)
Fig. 3. Intestinal permeability and absorptive function. Disacchar
for intestinal permeability The gray area represents abnormal gut pe
values at each of the time points, results were unchanged before a
seven of eight participants after 8 weeks of bovine serum immunoBoth CD4þ and CD8þ T cells with the activated
phenotype remained unchanged over the 8 weeks of
the study: CD4þ T-cell activation – 6.6% (5.1–9.9) and
6.7% (4.2–12.9) and CD8þ T-cell activation – 20.1%
(17.8–27.9) and 20.3% (17.8–29.2). By flow cytometry,
duodenal tissue CD4þ T-cell percentage increased
minimally in six of eight participants with a median
increase of 1.2% (not significant) but remained
unchanged overall at 15.9% (12.0–26.6) at baseline and
15.5% (13.9–30.2) at week 8. However, by IFA, lamina
propria CD3þ/CD4þ lymphocytes (CD4þ LPL) inc-
reased from 213 cells/mm2 (152–243) to 322 cells/mm2
(228–433; P¼ 0.016; Fig. 4a). This represented a rise of
139.5 cells/mm2 (66.1–216) after 8weeks of SBI.Whereas
the lamina propriaCD3þ/CD8þ (CD8þ LPL) densitywas
unchanged [502 cells/mm2 (416–650) and 598 cells/mm2
(361–699)] at baseline and week 8, respectively, the
lamina propria CD4þ/CD8þ ratio increased from 0.41horized reproduction of this article is prohibited.
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Fig. 4. Mucosal immune reconstitution. Immunofluorescent antibody assay (IFA) results for duodenal lamina propria
CD4þ lymphocyte densities (a) and CD4þ/CD8þ ratios (b) showed significant increases over the 8 weeks of bovine serum
immunoglobulin (SBI) administration. Compared to a cohort of HIV individuals naive to antiretroviral therapy who were assessed
for immune reconstitution in the duodenal lamina propria using identical methods, participants on SBI had a statistically significant
more robust recovery of lamina propria lymphocytes. (c) Although these are clinically different cohorts of participants, the
comparison provides a context to interpret the magnitude of the increase in mucosal CD4þ lymphocytes.(0.23–0.51) to 0.62 (0.34–0.99; P¼ 0.016; Fig. 4b).
We previously reported the impact of 9 months of
suppressive ART on CD4þ LPL density using identical
methods wherein an increase from 100.0 cells/mm2
(72–145.5) pre-ART to 140.5 cells/mm2 (126.7–170.8)
at month 9 was measured (P¼ 0.006) [16]. This
represented an increase of 57 cells/mm2 (9.0, 82) after
9 months of ART, which was significantly less than that
observed in the participants receiving 8 weeks of SBI
(Fig. 4c). To put these results in perspective, in a cohort
of 12 control volunteers of similar demographics and
lifestyle who have undergone identical procedures,
we have observed CD4þ and CD8þ LPL densities of
748.8 cells/mm2 (510.6–998.5) and 270.8 cells/mm2
(226.7, 557.5), respectively [16].
Biomarkers of inflammation, enterocyte damage,
and collagen kinetics
Circulating LPS (irrespective of vacutainer type), IL-1b,
IL-6, TNF-a, IFN-g, IL-12p70, IL-4, IL-10, and IL-8
were similar to the levels of controls at baseline and were
not changed at the EOT. Results from several parameters
were available among those who continued for 48 weeks
as described above. MCP-1 was higher in participants
at baseline than controls [476.4 ng/ml (426.4–598.1)
versus 336.6 ng/ml (307.9–400.8; P¼ 0.03)]. MCP-1
levels were unchanged at week 8, but decreased in five of
five participants at week 48 [379.5 ng/ml (225–502)
(P¼ 0.06); Fig. 5)].
We next examined I-FABP levels in serum. I-FABP
reflects enterocyte damage, is elevated in the setting of
HIV, and is negatively correlated with survival in recent
HIV studies [37,38]. Unexpectedly, the values initially
rose in seven of eight participants after 8 weeks from
3514 pg/ml (2858–4275) to 4042 pg/ml (3233–5613;
P¼ 0.039) and then fell below baseline in four of the fivepyright © Lippincott Williams & Wilkins. Unauthowho continued receiving SBI to 2442 pg/ml (1267–
2875; P¼ 0.12 compared to baseline and 0.06 compared
to week 8). Each of these timepoint results is signifi-
cantly higher in comparison to HIV-negative controls
[21.59 pg/ml (20.0–454.7) (P< 0.0001)].
Analysis of biomarkers of collagen kinetics provided
potential mechanistic explanation for the observed
increase in CD4 LPL. Although peripheral blood levels
of TGF-b 1, 2, or 3, and hyaluronic acid were not
different from those in the controls and did not decline
following SBI administration, MMP-9/TIMP-1 ratios
in participants were significantly lower than controls at
baseline [0.13 (0.07–0.33) versus 0.42 (0.23–0.44)
(P¼ 0.007)], respectively, and tended to increase at the
EOT to 0.33 (0.13–0.73; P¼ 0.08). MMP-2/TIMP-2
levels were not different from those in controls at baseline
and did not rise after SBI administration. MMP-2/
TIMP-2 and MMP-9/TIMP-1 ratios regulate reabsorp-
tion/repair of collagen deposition and have been reported
as abnormal in lymph nodes in HIV disease [39].
Finally, correlations were sought between lamina
propria lymphocyte subset densities and these biomarkers
of monocyte activation, enterocyte turnover, and
collagen kinetics (Fig. 5). MCP-1 levels were negatively
correlated to CD4þ LPL (r¼0.59, P¼ 0.019) with all
time points examined together, suggesting that MCP-1
expression is associated with mucosal immunologic
damage. Similarly, MMP-9/TIMP-1 ratios were nega-
tively correlated with CD8þ LPL density (r¼0.70,
P¼ 0.0039) suggesting that factors promoting CD8þ
T-cell infiltration into the lamina propria correlate
with impaired collagen kinetics. Finally, more severe
baseline enterocyte damage blunted the magnitude of
mucosal immunity recovery as baseline serum I-FABP
levels were negatively correlated with subsequent rise inrized reproduction of this article is prohibited.
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Fig. 5. Biomarkers of inflammation, enterocyte damage, and collagen kinetics. Monocyte chemoattractant protein-1 (MCP-1)
was elevated at baseline in this cohort of chronically virologically suppressed and fell in the five participants who continued
bovine serum immunoglobulin (SBI) for 48 weeks (a). MCP-1 levels negatively correlated with mucosal CD4þ lymphocyte density
suggesting that common pathways influence systemic inflammation and mucosal immunity (b). Similarly, a negative correlation
was observed between the biomarker of collagen kinetics, MMP-9/TIMP-1 ratios, and elevated concentrations of CD8þ
lymphocytes in the duodenal lamina propria (c). Perhaps as expected, evidence for higher levels of epithelial/enterocyte damage
at baseline correlated negatively with subsequent recovery of lamina propria CD4þ lymphocyte reconstitution following SBI
administration (d).CD4þ LPL (r¼0.74, P¼ 0.046). These data support
the hypothesis that HIV enteropathy presents in a
spectrum of severity and that GALT CD4þ T-cell
recovery is impaired in more severe enterocyte damage.Discussion
Serum-derived bovine immunoglobulin was serendipi-
tously discovered to reverse severe inflammatory diarrhea
in animal husbandry and has been available as a medical
food with GRAS FDA (generally regarded as safe – Food
andDrugAdministration) status since 2008 [40]. Extensive
investigations have demonstrated that SBI has broad
bacterial and viral antigen neutralizing capacity and reducesCopyright © Lippincott Williams & Wilkins. Unautintestinal inflammation [23,25–27,41–46]. It has been
tested in two clinical trials that confirmed its safety in
humans [28,47]. This pilot, proof-of-concept clinical trial
was designed to examine the impact of SBI on HIV
enteropathy with the primary focus on gut immunologic
and functional parameters. We observed a uniform
improvement in stool frequency, consistency, and gastro-
intestinal related symptoms in all participants over the
course of the 8-week intensive study with sustained
improvements in those who entered the 48-week
extension study. Notably, severe urgency, self-soiling,
and nighttime bowelmovements, indicative of highwater-
content stools, resolved during exposure to SBI and
returned in a subset of participants during the 4-week
‘washout period’. The five participants who opted to
continue the extension phase were those who reportedhorized reproduction of this article is prohibited.
Co
2214 AIDS 2013, Vol 27 No 14return of symptoms (except for one whowas subsequently
lost to follow-up).
Unexpectedly, we did not observe increased intestinal
permeability in this population of virologically suppressed
patients. The urine disaccharide assays were performed in
the same reference laboratory and methods as employed
in the early reports of increased permeability in untreated
AIDS patients and those with infectious diarrhea [30].
Sharpstone et al. reported lactulose/L-rhamnose mean
ratios of 0.03 (SD 0.01) in their normal controls and
0.04 (SD 0.5) in their asymptomatic AIDS patients,
which we reproduced in our cohort 0.03 (0.02), overall.
However, they did report abnormal ratios (>0.05) in their
AIDS patients with weight loss and pathogen-negative
diarrhea (means of 0.14 and 0.15, respectively), which
represent a very different population in the pre-HAART
era than our cohort of chronically virologically suppressed
patients [30]. Increased intestinal permeability is only
one reason for increased bacterial translocation. Other
conditions, such as bacterial overgrowth syndrome,
demonstrate increased bacterial antigen translocation
with normal intestinal permeability [48]. This report
suggests that the mechanisms behind bacterial trans-
location in HIV patients are due to pathways other than
increased macromolecule permeability.
The improved D-xylose absorption was modest but was
observed in seven of eight participants after 7 weeks of
SBI. Interestingly, the one participant who did not
demonstrate increased absorptive function also did not
show an increase in duodenal CD4þ T-cell density.
Longer observation periods are needed to confirm the
improved gut function with SBI administration.
This is the first intervention that demonstrates a substantial
increase in duodenal GALT lymphocyte populations
in HIV patients. Although the pathologic mechanisms
underlying delayedCD4þT-cell immune reconstitution in
duodenal lamina propria are unknown, several authors
have noted increased collagen staining in both intestinal
and lymphnode tissue [49–52].The disrupted architecture
may lead to disruption of critical cellular maturational
interactions mediated by cytokine homeostasis [53]. In
addition, an inverse correlation between cross-sectional
area of collagen stained and CD4þ T-cell stained tissue in
the small intestines has been observed [50]. The initiating
events triggering the profibrotic pathways are believed to
be a consequence ofHIV infection itself andmanifested by
a broad range of cytokine-mediated immune activation
including IL-6, TGF-b, and hyaluronic acid – all key
contributors to collagen deposition [54–57]. Interestingly,
in this cohort of virologically suppressed patients, we did
not identify increased systemic levels of any of these
or related inflammatory markers, including hsCRP or
D-dimer (data not shown) when compared to a cohort
of HIV-negative controls. However, the elevated levels of
MCP-1 and depressed levels of MMP-9/TIMP-1 ratiospyright © Lippincott Williams & Wilkins. Unauthodescribe an environment of monocyte inflammation
and migration to the effector site of the lamina propria
coupled with abnormal collagen kinetics. Wound repair,
collagen deposition, and fibrosis are tightly regulated
processes entailing multiple potential pathways with
compensatory mechanisms for collagen reabsorption that
is primarily performed by the matrix metalloproteinases
and modulated by TIMP [58–60]. In addition, MCP-1
is one of several important regulators of fibrosis [61].
The persistence of abnormal levels ofMCP-1 and MMP-
9/TIMP-1 has been noted previously in HIV patients
[39,62]. This persistence likely reflects events that are
ongoing and uncontrolled in the setting ofHIV suppressive
therapy.Correlations betweenMCP-1 andCD4þLPL and
between MMP-9/TIMP-1 ratios and CD8þ LPL further
suggest that these parameters are linked to sustained,
uncontrolled antigenic stimulation at the gut mucosal
interface. The observation that I-FABP increased in
all participants acutely and then fell to below baseline
in four of five participants suggests a biological explanation
for the clinical improvements and increased absorption
function. I-FABP is a marker for enterocyte damage
that has been validated in coeliac disease response to a
gluten-free diet. It is also related to repair and proliferation
among other important cellular pathways [63,64]. The
initial increase may reflect enterocyte repair and turnover
following neutralization of damaging inflammatory
bacterial antigen by SBI. The strong correlation between
baseline I-FABP levels and subsequent recovery in
CD4þ LPL following SBI administration is consistent
with the hypothesis that neutralization of bacterial antigen
promotes improved clinical, functional, and immunologic
composition of the duodenal mucosal compartment.
The absence of circulating CD4þ T-cell count increases
likely reflects the complex architectural and functional
abnormalities that will require a longer duration of
treatment and observation to reverse. Longer duration
studies are planned to test this hypothesis.
NexGen sequencing analysis of the gut microbiota is
ongoing to demonstrate the impact of SBI on gut
microbiota as well as gastrointestinal functional and
immunologic parameters. Sustained reversal of ongoing
profibrotic pathways and interruption of collagen repair
in the setting of HIV disease are needed to restore the
mucosal immune system to preinfection levels.Acknowledgements
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